Status:
UNKNOWN
RPCRC Validation Study
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Multivariate Risk Assessment for ISUP ≥2 Prostate Cancer
Eligibility:
MALE
18-75 years
Brief Summary
Prostate multiparametric MRI (mpMRI) can detect ISUP ≥2 prostate cancer with high sensitivity. Adding biopsies targeting suspicious lesions seen on mpMRI to the classical 'systematic biopsies' (that s...
Eligibility Criteria
Inclusion
- Patient referred for mpMRI and prostate biopsy due to increased PSA level, abnormal DRE or family history of prostate cancer.
- Age ≤75 years
- PSA level ≤20 ng/mL
- Clinical stage ≤T2c
Exclusion
- Contraindication for prostate mpMRI or biopsy
- History of hip prosthesis, androgen deprivation therapy, pelvic radiotherapy or prostate cancer diagnosed after trans-urethral resection of the prostate.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
275 Patients enrolled
Trial Details
Trial ID
NCT04484103
Start Date
January 1 2020
End Date
September 1 2020
Last Update
July 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiology, Hôpital Edouard Herriot, Hospices Civils de Lyon
Lyon, France, 69008